- The Phase IIa, proof of clinical principle study, had its first patient dosed in the USA
- A new drug formulation is expected to improve target organ drug delivery and distribution
- The new formulation of BBT-401 demonstrated greater drug recovery in the colon and ileum via the in vitro SHIME® Model
SEONGNAM, South Korea, June 14, 2021 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330) announced today the first patient dosing of BBT-401 at mid to high doses in its proof of clinical principle (PoCP) study to examine the drug's efficacy and safety in active ulcerative colitis (NCT04596293).
The Phase IIa, is a two-phase study, with a randomized, double-blind, placebo-controlled induction phase, followed by a response-adaptive, double-blind extension phase. This multinational study will assess the safety and efficacy profiles of the investigational drug in 36 patients with moderate to severe ulcerative colitis, by activating 36 clinical trial sites across 5 countries (USA, Republic of Korea, New Zealand, Poland and Ukraine).
The primary and secondary endpoints of the study consist of efficacy and safety assessments measured 8 weeks after drug administration. These include the clinical response and remission rates determined from the total Mayo score as well as the endoscopic remission rate, which is calculated based on the Mayo endoscopic subscore.
Upon the completion of the low dose study, which was the first-in-patient study for BBT-401, the drug formulation has been enhanced in terms of its drug delivery and distribution to the ileum and distant colon. The enhanced drug delivery and distribution profile was evaluated via the in vitro Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) model.
BBT-401, an investigational drug with the potential to exhibit treatment efficacy in inflammatory diseases such as ulcerative colitis, is a GI-tract restricted small molecule Pellino-1 inhibitor. Pellino proteins serve as scaffold proteins that bind to proteins in inflammatory signaling pathways, including IRAK4, MyD88 and to RIPK1 in various physio-pathological conditions.
"Given the improved drug formulation of BBT-401, we are hoping to observe enhanced treatment responses in the moderate to severe UC patients," and "our team will continue to focus on the development of a breakthrough treatment for active ulcerative colitis patients. Additionally, our goal is to disclose the interim data of the study in the first half of 2022," said James Lee, CEO of Bridge Biotherapeutics.
In conjunction with the orally administered PoCP study, a proof of mechanism trial has been initiated in New Zealand, exploring the efficacy and safety of a rectal administration of BBT-401 in patients with active ulcerative colitis.
About Bridge Biotherapeutics
Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs such as ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations.